These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 1736981)

  • 21. Patients with early stage invasive cancer with close or positive margins treated with conservative surgery and radiation have an increased risk of breast recurrence that is delayed by adjuvant systemic therapy.
    Freedman G; Fowble B; Hanlon A; Nicolaou N; Fein D; Hoffman J; Sigurdson E; Boraas M; Goldstein L
    Int J Radiat Oncol Biol Phys; 1999 Jul; 44(5):1005-15. PubMed ID: 10421533
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Adjuvant systemic therapy for patients with resectable breast cancer: guideline from the Dutch National Breast Cancer Platform and the Dutch Society for Medical Oncology].
    Bontenbal M; Nortier JW; Beex LV; Bakker P; Hupperets PS; Nooij MA; van Veelen H; Vreugdenhil G; Richel DJ; Blijham GH
    Ned Tijdschr Geneeskd; 2000 May; 144(21):984-9. PubMed ID: 10858788
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adjuvant docetaxel for high-risk, node-negative breast cancer.
    Martín M; Seguí MA; Antón A; Ruiz A; Ramos M; Adrover E; Aranda I; Rodríguez-Lescure A; Grosse R; Calvo L; Barnadas A; Isla D; Martinez del Prado P; Ruiz Borrego M; Zaluski J; Arcusa A; Muñoz M; López Vega JM; Mel JR; Munarriz B; Llorca C; Jara C; Alba E; Florián J; Li J; López García-Asenjo JA; Sáez A; Rios MJ; Almenar S; Peiró G; Lluch A;
    N Engl J Med; 2010 Dec; 363(23):2200-10. PubMed ID: 21121833
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients.
    Harbeck N; Schmitt M; Meisner C; Friedel C; Untch M; Schmidt M; Sweep CG; Lisboa BW; Lux MP; Beck T; Hasmüller S; Kiechle M; Jänicke F; Thomssen C;
    Eur J Cancer; 2013 May; 49(8):1825-35. PubMed ID: 23490655
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is axillary lymph node dissection indicated for early-stage breast cancer? A decision analysis.
    Parmigiani G; Berry DA; Winer EP; Tebaldi C; Iglehart JD; Prosnitz LR
    J Clin Oncol; 1999 May; 17(5):1465-73. PubMed ID: 10334532
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Who should not undergo breast conservation?
    Nijenhuis MV; Rutgers EJ
    Breast; 2013 Aug; 22 Suppl 2():S110-4. PubMed ID: 24074770
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER).
    Bueno-de-Mesquita JM; van Harten WH; Retel VP; van 't Veer LJ; van Dam FS; Karsenberg K; Douma KF; van Tinteren H; Peterse JL; Wesseling J; Wu TS; Atsma D; Rutgers EJ; Brink G; Floore AN; Glas AM; Roumen RM; Bellot FE; van Krimpen C; Rodenhuis S; van de Vijver MJ; Linn SC
    Lancet Oncol; 2007 Dec; 8(12):1079-1087. PubMed ID: 18042430
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Effective treatment strategy in elderly breast cancer patients].
    Boér K
    Orv Hetil; 2005 Jan; 146(1):15-21. PubMed ID: 15715368
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
    Lancet; 1998 Sep; 352(9132):930-42. PubMed ID: 9752815
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
    Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
    Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.
    Jänicke F; Prechtl A; Thomssen C; Harbeck N; Meisner C; Untch M; Sweep CG; Selbmann HK; Graeff H; Schmitt M;
    J Natl Cancer Inst; 2001 Jun; 93(12):913-20. PubMed ID: 11416112
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness of adjuvant chemotherapy for node-positive operable breast cancer in older women.
    Du XL; Jones DV; Zhang D
    J Gerontol A Biol Sci Med Sci; 2005 Sep; 60(9):1137-44. PubMed ID: 16183952
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term follow-up of axillary node-positive breast cancer patients receiving adjuvant systemic therapy alone: patterns of recurrence.
    Fisher BJ; Perera FE; Cooke AL; Opeitum A; Venkatesan V; Dar AR; Stitt L
    Int J Radiat Oncol Biol Phys; 1997 Jun; 38(3):541-50. PubMed ID: 9231678
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Breast cancer in young women in the south of Tunisia].
    Khanfir A; Frikha M; Kallel F; Meziou M; Trabelsi K; Boudawara T; Mnif J; Daoud J
    Cancer Radiother; 2006 Dec; 10(8):565-71. PubMed ID: 17140835
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of adjuvant tamoxifen: the latest results from the Cancer Research Campaign Adjuvant Breast Trial. Cancer Research Campaign Breast Cancer Trials Group.
    Eur J Cancer; 1992; 28A(4-5):904-7. PubMed ID: 1524921
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer.
    Powles TJ; Hickish TF; Makris A; Ashley SE; O'Brien ME; Tidy VA; Casey S; Nash AG; Sacks N; Cosgrove D
    J Clin Oncol; 1995 Mar; 13(3):547-52. PubMed ID: 7884414
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adjuvant trastuzumab reduces locoregional recurrence in women who receive breast-conservation therapy for lymph node-negative, human epidermal growth factor receptor 2-positive breast cancer.
    Kiess AP; McArthur HL; Mahoney K; Patil S; Morris PG; Ho A; Hudis CA; McCormick B
    Cancer; 2012 Apr; 118(8):1982-8. PubMed ID: 21887681
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The influence of young age on outcome in early stage breast cancer.
    Fowble BL; Schultz DJ; Overmoyer B; Solin LJ; Fox K; Jardines L; Orel S; Glick JH
    Int J Radiat Oncol Biol Phys; 1994 Aug; 30(1):23-33. PubMed ID: 8083119
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumour epidermal growth factor receptor, erbB-2 and cathepsin D in node-negative invasive breast cancer: their impact on the selection of patients for systemic adjuvant therapy.
    Tonkin KS; McKay JW; Stitt LW; Tokmakejian S; Haines DS
    Cancer Prev Control; 1999 Apr; 3(2):131-6. PubMed ID: 10474760
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized clinical trial of adjuvant fluorouracil, epirubicin, and cyclophosphamide chemotherapy for patients with fast-proliferating, node-negative breast cancer.
    Paradiso A; Schittulli F; Cellamare G; Mangia A; Marzullo F; Lorusso V; De Lena M
    J Clin Oncol; 2001 Oct; 19(19):3929-37. PubMed ID: 11579113
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.